# Core12 â€“ PDB-based Rationale for Sequence Improvements


**Antibody_A (VH, position 28)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 30)**

Aromatic residue **F** in CDR-H3 was substituted with **L** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 37)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 59)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 107)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 110)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 111)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 113)**

Aromatic residue **W** in CDR-H3 was substituted with **H** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 114)**

Aromatic residue **Y** in CDR-H3 was substituted with **S** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_A (VH, position 115)**

Aromatic residue **F** in CDR-H3 was substituted with **L** to reduce
surface-exposed aromatic clustering. Structural surveys of therapeutic antibodies
(PDB-derived analyses; Raybould et al., 2019) show that aromatic-rich CDR patches
frequently participate in self-association interfaces, increasing aggregation and
polyspecificity risk. Polar substitution preserves loop geometry while mitigating
non-specific hydrophobic interactions.

**Antibody_B (VH, position 6)**

Framework hydrophobic residue **V** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VH, position 10)**

Framework hydrophobic residue **A** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VH, position 17)**

Framework hydrophobic residue **L** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VH, position 46)**

Framework hydrophobic residue **L** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VH, position 50)**

Framework hydrophobic residue **V** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VH, position 79)**

Framework hydrophobic residue **L** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VL, position 3)**

Framework hydrophobic residue **V** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VL, position 18)**

Framework hydrophobic residue **L** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VL, position 47)**

Framework hydrophobic residue **L** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_B (VL, position 99)**

Framework hydrophobic residue **F** was replaced with **S** to disrupt
extended hydrophobic surface patches. PDB analyses of high-viscosity antibodies
(Jain et al., 2017) indicate that such framework-exposed hydrophobic clusters,
rather than CDR residues, are primary drivers of poor formulation behavior.

**Antibody_C (VH, position 55)**

Liability-associated residue **NG** was substituted with **nan** to reduce
chemical instability. Motifs such as DG/NG and acidic clusters are frequently
implicated in deamidation and cleavage events observed in clinical-stage antibodies
(Sharma et al., 2014). The proposed substitution reduces chemical reactivity without
altering antigen-contact residues.

**Antibody_C (VH, position 102)**

Liability-associated residue **DG** was substituted with **DA** to reduce
chemical instability. Motifs such as DG/NG and acidic clusters are frequently
implicated in deamidation and cleavage events observed in clinical-stage antibodies
(Sharma et al., 2014). The proposed substitution reduces chemical reactivity without
altering antigen-contact residues.

**Antibody_C (VH, position 57)**

Liability-associated residue **D** was substituted with **N** to reduce
chemical instability. Motifs such as DG/NG and acidic clusters are frequently
implicated in deamidation and cleavage events observed in clinical-stage antibodies
(Sharma et al., 2014). The proposed substitution reduces chemical reactivity without
altering antigen-contact residues.

**Antibody_C (VH, position 105)**

Liability-associated residue **D** was substituted with **N** to reduce
chemical instability. Motifs such as DG/NG and acidic clusters are frequently
implicated in deamidation and cleavage events observed in clinical-stage antibodies
(Sharma et al., 2014). The proposed substitution reduces chemical reactivity without
altering antigen-contact residues.